ERBB2 and breast carcinoma: Cohort 1 (Pembrolizumab, Doxorubicin Hydrochloride) Triple Negative Breast Cancer    Cohort 2 (Pembrolizumab, Anti-estrogen Therapy) HR + HER2- Breast Cancer